A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade

Trial Profile

A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Pembrolizumab (Primary) ; Peptide vaccines (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PATHVACS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Apr 2016 Time frame for primary endpoint adverse events changed from 90 days after the last administration of study drug to 30 days after the last administration of study drug.
    • 19 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top